Expert review of the evidence base for self-therapy of travelers' diarrhea

Journal of Travel Medicine

Volumn 16, Issue 3, 2009, Pages 161-171

  Dupont, Herbert L ^a,b,c,d   Ericsson, Charles D ^b   Farthing, Michael J G ^e   Gorbach, Sherwood ^f   Pickering, Larry K ^g   Rombo, Lars ^h,i   Steffen, Robert ^j   Weinke, Thomas ^k  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c St Luke's Episcopal Hospital   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF BRIGHTON   (United Kingdom)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ Sormland County Council   (Sweden)

^j UNIVERSITY OF ZURICH   (Switzerland)

^k KLINIKUM ERNST VON BERGMANN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETORPHAN; ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; AZITHROMYCIN; BISMUTH SALICYLATE; CIPROFLOXACIN; COTRIMOXAZOLE; CROFELEMER; LEVOFLOXACIN; LOPERAMIDE; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; STOMACH SECRETION INHIBITOR; ZALDARIDE MALEATE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIARRHEA; DIET RESTRICTION; DOSAGE SCHEDULE COMPARISON; DRUG FECES LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION CONTROL; INFECTION RISK; INSOMNIA; IRRITABILITY; MONOTHERAPY; ORAL REHYDRATION THERAPY; OUTCOME ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH EROSION; STOMACH HEMORRHAGE; TRAVELLER DIARRHEA; VAGINA CANDIDIASIS;

ANTI-BACTERIAL AGENTS; ANTIDIARRHEALS; BISMUTH; DEVELOPING COUNTRIES; DIARRHEA; EVIDENCE-BASED MEDICINE; HUMANS; LOPERAMIDE; ORGANOMETALLIC COMPOUNDS; SALICYLATES; TRAVEL;

EID: 65649097696     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/j.1708-8305.2009.00300.x     Document Type: Article

References (112)

1. Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis 2001 32 : 1706 1709. (Pubitemid 32531999)
2. Black RE. Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis 1990 12 (Suppl 1 S73 S79. (Pubitemid 20060287)
3. Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002 185 : 497 502. (Pubitemid 34142812)
4. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 2006 74 : 1060 1066.
5. Tribble DR, Sanders JW, Pang LW, et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007 44 : 338 346. (Pubitemid 46147614)
6. Ko G, Garcia C, Jiang ZD, et al. Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. J Clin Microbiol 2005 43 : 6126 6129. (Pubitemid 43100672)
7. DuPont HL, Capsuto EG. Persistent diarrhea in travelers. Clin Infect Dis 1996 22 : 124 128. (Pubitemid 26022021)
8. King CK, Glass R, Bresee JS, Duggan C. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003 52 (RR-16 1 16.
9. Kielmann AA, Mobarak AB, Hammamy MT, et al. Control of deaths from diarrheal disease in rural communities. I. Design of an intervention study and effects on child mortality. Trop Med Parasitol 1985 36 : 191 198. (Pubitemid 16177089)
10. Victora CG, Bryce J, Fontaine O, Monasch R. Reducing deaths from diarrhoea through oral rehydration therapy. Bull World Health Organ 2000 78 : 1246 1255.
11. Pierce NF, Banwell JG, Mitra RC, et al. Oral replacement of water and electrolyte losses in cholera. Indian J Med Res 1969 57 : 848 855.
12. Caeiro JP, DuPont HL, Albrecht H, Ericsson CD. Oral rehydration therapy plus loperamide versus loperamide alone in the treatment of traveler's diarrhea. Clin Infect Dis 1999 28 : 1286 1289. (Pubitemid 29272804)
13. Duggan C, Santosham M, Glass RI. The management of acute diarrhea in children: oral rehydration, maintenance, and nutritional therapy. Centers for Disease Control and Prevention. MMWR Recomm Rep 1992 41 (RR-16 1 20.
14. Huang DB, Awasthi M, Le BM, et al. The role of diet in the treatment of travelers' diarrhea: a pilot study. Clin Infect Dis 2004 39 : 468 471. (Pubitemid 39120919)
15. Brown KH, Peerson JM, Fontaine O. Use of nonhuman milks in the dietary management of young children with acute diarrhea: a meta-analysis of clinical trials. Pediatrics 1994 93 : 17 27. (Pubitemid 24012123)
16. DuPont HL, Flores Sanchez J, Ericsson CD, et al. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am J Med 1990 88 (6A 15S 19S. (Pubitemid 20189091)
17. DuPont HL, Sullivan P, Pickering LK, Haynes G, et al. Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university. Gastroenterology 1977 73 (4 Pt 1 715 718. (Pubitemid 8210065)
18. Johnson PC, Ericsson CD, DuPont HL, Morgan DR, et al. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea. JAMA 1986 255 : 757 760. (Pubitemid 16161434)
19. Powell DW, Tapper EJ, Morris SM. Aspirin-stimulated intestinal electrolyte transport in rabbit ileum in vitro. Gastroenterology 1979 76 : 1429 1437. (Pubitemid 9195827)
20. Burke V, Gracey M, Suharyono, Sunoto. Reduction by aspirin of intestinal fluid-loss in acute childhood gastroenteritis. Lancet 1980 1 (8182 1329 30. (Pubitemid 10063298)
21. Venerito M, Treiber G, Wex T, et al. Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol Ther 2006 23 : 1225 1233. (Pubitemid 43779363)
22. Gilster J, Bacon K, Marlink K, et al. Bismuth subsalicylate increases intracellular Ca2+, MAP-kinase activity, and cell proliferation in normal human gastric mucous epithelial cells. Dig Dis Sci 2004 49 : 370 378. (Pubitemid 38453550)
23. Epple HJ, Fromm M, Riecken EO, Schulzke JD. Antisecretory effect of loperamide in colon epithelial cells by inhibition of basolateral K+ conductance. Scand J Gastroenterol 2001 36 : 731 737. (Pubitemid 32568551)
24. DuPont HL, Ericsson CD, Mathewson JJ, et al. Zaldaride maleate, an intestinal calmodulin inhibitor, in the therapy of travelers' diarrhea. Gastroenterology 1993 104 : 709 715. (Pubitemid 23059568)
25. DiCesare D, DuPont HL, Mathewson JJ, et al. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol 2002 97 : 2585 2588.
26. Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, Gutierrez M. Racecadotril in the treatment of acute watery diarrhea in children. N Engl J Med 2000 343 : 463 467. (Pubitemid 30646485)
27. Wang HH, Shieh MJ, Liao KF. A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults. World J Gastroenterol 2005 11 : 1540 1543. (Pubitemid 40468093)
28. DuPont HL, Olarte J, Evans DG, et al. Comparative susceptibility of latin american and united states students to enteric pathogens. N Engl J Med 1976 295 : 1520 1521. (Pubitemid 8014698)
29. Gorbach SL, Kean BH, Evans DG, Evans DJ, Jr., et al. Travelers' diarrhea and toxigenic Escherichia coli. N Engl J Med 1975 292 : 933 936.
30. Merson MH, Morris GK, Sack DA, et al. Travelers' diarrhea in Mexico. A prospective study of physicians and family members attending a congress. N Engl J Med 1976 294 : 1299 1305.
31. DuPont HL, Reves RR, Galindo E, Sullivan PS, et al. Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med 1982 307 : 841 844. (Pubitemid 12067890)
32. DuPont HL, Cooperstock M, Corrado ML, Fekety R, et al. Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992 15 Suppl. 1 : S228 S235.
33. Salam I, Katelaris P, Leigh-Smith S, Farthing MJ. Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Lancet 1994 344 : 1537 1539. (Pubitemid 24357711)
34. Gomi H, Jiang ZD, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001 45 : 212 216. (Pubitemid 32039117)
35. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001 33 : 1807 1815. (Pubitemid 33105118)
36. Bennish ML, Salam MA, Khan WA, Khan AM. Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann Intern Med 1992 117 : 727 734.
37. Kabir I, Butler T, Khanam A. Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial. Antimicrob Agents Chemother 1986 29 : 645 648. (Pubitemid 16106388)
38. Zhang X, McDaniel AD, Wolf LE, et al. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000 181 : 664 670. (Pubitemid 30131837)
39. Ohara T, Kojio S, Taneike I, et al. Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother 2002 46 : 3478 3483. (Pubitemid 35192914)
40. Kimmitt PT, Harwood CR, Barer MR. Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis 2000 6 : 458 465.
41. Ochoa TJ, Chen J, Walker CM, Gonzales E, et al. Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother 2007 51 : 2837 2841. (Pubitemid 47206219)
42. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 2002 288 : 996 1001. (Pubitemid 36014127)
43. Bennish ML, Khan WA, Begum M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis 2006 42 : 356 362. (Pubitemid 43122310)
44. Neill MA, Opal SM, Heelan J, et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med 1991 114 : 195 199.
45. Sanchez C, Garcia-Restoy E, Garau J, et al. Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis: a double-blind trial. J Infect Dis 1993 168 : 1304 1307. (Pubitemid 23317157)
46. Musher DM, Rubenstein AD. Permanent carriers of nontyphosa salmonellae. Arch Intern Med 1973 132 : 869 872.
47. Sirinavin S, Garner P. Antibiotics for treating salmonella gut infections. Cochrane Database Syst Rev 2000 : CD001167.
48. Johnson PC, Ericsson CD, Morgan DR, et al. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin. Antimicrob Agents Chemother 1986 30 : 671 674. (Pubitemid 17187691)
49. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005 353 : 2433 2441. (Pubitemid 41770164)
50. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005 41 : 1254 1260. (Pubitemid 41532667)
51. Norman F, Perez-Molina J, de Ayala P, et al. Clostridium difficile-associated diarrhea after antibiotic treatment for traveler's diarrhea. Clin Infect Dis 2008 46 : 1060 1063.
52. Bennish ML, Salam MA, Hossain MA, et al. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infect Dis 1992 14 : 1055 1060.
53. Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA, 1982-2001. Emerg Infect Dis 2002 8 : 1501 1503. (Pubitemid 36008792)
54. Prats G, Mirelis B, Llovet T, et al. Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985-1987 and 1995-1998 in Barcelona. Antimicrob Agents Chemother 2000 44 : 1140 1145. (Pubitemid 30228285)
55. Saenz Y, Zarazaga M, Lantero M, et al. Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997-1998. Antimicrob Agents Chemother 2000 44 : 267 271. (Pubitemid 30060717)
56. Vila J, Vargas M, Ruiz J, et al. Quinolone resistance in enterotoxigenic Escherichia coli causing diarrhea in travelers to India in comparison with other geographical areas. Antimicrob Agents Chemother 2000 44 : 1731 1733. (Pubitemid 30340828)
57. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005 41 : 118 121. (Pubitemid 40863754)
58. Haukka K, Siitonen A. Emerging resistance to newer antimicrobial agents among Shigella isolated from Finnish foreign travellers. Epidemiol Infect 2007 136 : 1 7.
59. Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998 26 : 341 345. (Pubitemid 28083944)
60. Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995 21 : 536 541.
61. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003 37 : 1165 1171. (Pubitemid 37372503)
62. Khan WA, Seas C, Dhar U, et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997 126 : 697 703. (Pubitemid 27184040)
63. Kassenborg HD, Smith KE, Vugia DJ, et al. Fluoroquinolone-resistant Campylobacter infections: eating poultry outside of the home and foreign travel are risk factors. Clin Infect Dis 2004 38 Suppl. 3 : S279 S284. (Pubitemid 38553335)
64. Wardak S, Szych J, Zasada AA, Gierczynski R. Antibiotic resistance of Campylobacter jejuni and Campylobacter coli clinical isolates from Poland. Antimicrob Agents Chemother 2007 51 : 1123 1125. (Pubitemid 46355312)
65. Sierra JM, Ruiz J, Navia MM, et al. In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea. Antimicrob Agents Chemother 2001 45 : 643 644. (Pubitemid 32105314)
66. Engberg J, Aarestrup FM, Taylor DE, et al. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001 7 : 24 34. (Pubitemid 32173330)
67. Gupta A, Nelson JM, Barrett TJ, et al. Antimicrobial resistance among Campylobacter strains, United States, 1997-2001. Emerg Infect Dis 2004 10 : 1102 1109. (Pubitemid 38697705)
68. Sanders JW, Isenbarger DW, Walz SE, et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg 2002 67 : 533 538. (Pubitemid 35403172)
69. Coker AO, Adefeso AO. The changing patterns of Campylobacter jejuni/coli in Lagos, Nigeria after ten years. East Afr Med J 1994 71 : 437 440.
70. Li CC, Chiu CH, Wu JL, Huang YC, et al. Antimicrobial susceptibilities of Campylobacter jejuni and coli by using E-test in Taiwan. Scand J Infect Dis 1998 30 : 39 42. (Pubitemid 28312734)
71. Gaudreau C, Gilbert H. Antimicrobial resistance of Campylobacter jejuni subsp. jejuni strains isolated from humans in 1998 to 2001 in Montreal, Canada. Antimicrob Agents Chemother 2003 47 : 2027 2029. (Pubitemid 36637839)
72. Gaudreau C, Michaud S. Cluster of erythromycin- and ciprofloxacin- resistant Campylobacter jejuni subsp. jejuni from 1999 to 2001 in men who have sex with men, Quebec, Canada. Clin Infect Dis 2003 37 : 131 136. (Pubitemid 36836654)
73. Taylor DE, Chang N. In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin. Antimicrob Agents Chemother 1991 35 : 1917 1918.
74. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004 99 : 1774 1778. (Pubitemid 39237507)
75. Stermer E, Lubezky A, Potasman I, et al. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis 2006 43 : 898 901. (Pubitemid 44435519)
76. Thornley JP, Jenkins D, Neal K, et al. Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis 2001 184 : 606 609. (Pubitemid 32783552)
77. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002 51 : 410 413.
78. Tornblom H, Holmvall P, Svenungsson B, Lindberg G. Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. Clin Gastroenterol Hepatol 2007 5 : 461 464. (Pubitemid 46575368)
79. Ericsson CD, DuPont HL, Mathewson JJ. Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler's diarrhea. J Travel Med 1997 4 : 3 7. (Pubitemid 27200248)
80. Ericsson CD, DuPont HL, Mathewson JJ, et al. Treatment of traveler's diarrhea with sulfamethoxazole and trimethoprim and loperamide. JAMA 1990 263 : 257 261. (Pubitemid 20025980)
81. Ericsson CD, Nicholls-Vasquez I, DuPont HL, Mathewson JJ. Optimal dosing of trimethoprim-sulfamethoxazole when used with loperamide to treat traveler's diarrhea. Antimicrob Agents Chemother 1992 36 : 2821 2824.
82. Petruccelli BP, Murphy GS, Sanchez JL, et al. Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J Infect Dis 1992 165 : 557 560.
83. Taylor DN, Sanchez JL, Candler W, et al. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann Intern Med 1991 114 : 731 734.
84. DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973 226 : 1525 1528.
85. Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990 162 : 711 716. (Pubitemid 20266164)
86. Ambrose PG. Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints. Treat Respir Med 2005 4 (Suppl 1 5 11. (Pubitemid 40485022)
87. Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 2007 45 (Suppl 2 S129 S136. (Pubitemid 47328627)
88. Cofsky RD, duBouchet L, Landesman SH. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother 1984 26 : 110 111. (Pubitemid 14086738)
89. DuPont HL, Ericsson CD, Robinson A, Johnson PC. Current problems in antimicrobial therapy for bacterial enteric infection. Am J Med 1987 82 (4A 324 328. (Pubitemid 18124467)
90. Heimdahl A, Kager L, Nord CE. Changes in the oropharyngeal and colon microflora in relation to antimicrobial concentrations in saliva and faeces. Scand J Infect Dis Suppl 1985 44 : 52 58. (Pubitemid 15056610)
91. Jiang ZD, Ke S, Palazzini E, Riopel L, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000 44 : 2205 2206. (Pubitemid 30484455)
92. Rakita RM, Jacques-Palaz K, Murray BE. Intracellular activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 1994 38 : 1915 1921. (Pubitemid 24278779)
93. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003 98 : 1073 1078. (Pubitemid 36733769)
94. Ericsson CD, DuPont HL, Mathewson JJ, Johnson PC, et al. Test-of-cure stool cultures for traveler's diarrhea. J Clin Microbiol 1988 26 : 1047 1049. (Pubitemid 18113071)
95. Jiang ZD, Ke S, Shao R, DuPont H. Rifaximin alteration of microbial virulence of enterotoxigenic Escherichia coli. 9th Conference International Soc Travel Med, Lisbon, Portugal (Abstract P0031.14). 2005 May 2.
96. Morrow AL, Pickering LK. Human milk and infectious diseases. In: Long S, Pickering, LK, Prober, CG, eds. Principles and practice of pediatric infectious diseases. 2nd Ed. Philadelphia: Churchill-Livingstone, 2002 : 80 87.
97. Pickering LK, Feldman S, Ericsson CD, Cleary TG. Absorption of salicylate and bismuth from a bismuth subsalicylate - containing compound (Pepto-Bismol). J Pediatr 1981 99 : 654 656. (Pubitemid 12232116)
98. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, et al. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 1979 51 : 177 187. (Pubitemid 10198928)
99. Forsythe CT, Ernst ME. Do fluoroquinolones commonly cause arthropathy in children? CJEM 2007 9 : 459 462.
100. Ruuskanen O. Safety and tolerability of azithromycin in pediatric infectious diseases: 2003 update. Pediatr Infect Dis J 2004 23 (2 Suppl S135 S139. (Pubitemid 38222808)
101. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 1994 18 : 421.
102. Ericsson CD, Johnson PC, DuPont HL, et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. Ann Intern Med 1987 106 : 216 220. (Pubitemid 17009880)
103. DuPont HL, Ericsson CD, Mathewson JJ, DuPont MW. Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study. Antimicrob Agents Chemother 1992 36 : 87 91.
104. Wistrom J, Jertborn M, Hedstrom SA, et al. Short-term self-treatment of travellers' diarrhoea with norfloxacin: a placebo-controlled study. J Antimicrob Chemother 1989 23 : 905 913. (Pubitemid 19181251)
105. Mattila L, Peltola H, Siitonen A, Kyronseppa H, et al. Short-term treatment of traveler's diarrhea with norfloxacin: a double-blind, placebo-controlled study during two seasons. Clin Infect Dis 1993 17 : 779 782. (Pubitemid 23293393)
106. Ericsson CD, DuPont HL, Mathewson JJ. Optimal dosing of ofloxacin with loperamide in the treatment of non-dysenteric travelers' diarrhea. J Travel Med 2001 8 : 207 209. (Pubitemid 33143863)
107. Ericsson CD, DuPont HL, Okhuysen PC, Jiang ZD, et al. Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone. J Travel Med 2007 14 : 312 319. (Pubitemid 47460252)
108. DuPont HL, Jiang ZD, Belkind-Gerson J, et al. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007 5 : 451 456. (Pubitemid 46575371)
109. Mendelowitz PC, Hoffman RS, Weber S. Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy. Ann Intern Med 1990 112 : 140 141. (Pubitemid 20022695)
110. Portnoy BL, DuPont HL, Pruitt D, Abdo JA, et al. Antidiarrheal agents in the treatment of acute diarrhea in children. JAMA 1976 236 : 844 846.
111. Reves R, Bass P, DuPont HL, Sullivan P, et al. Failure to demonstrate effectiveness of an anticholinergic drug in the symptomatic treatment of acute travelers' diarrhea. J Clin Gastroenterol 1983 5 : 223 227.
112. Ahmad SR. Lomotil overdose. Pediatrics 1992 89 (5 Pt 1 980 981.